Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive metastatic non-small-cell lung cancer [ID6177]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TS ID 11950Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer TS ID 12007Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer TS ID 12010Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC